Shilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Therapeutic Candidate
-
Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.
-
The collaboration will accelerate the development of G2B-002 and further validates Gate2Brain’s proprietary blood-brain barrier delivery platform.
-
The collaboration supports the development of innovative therapies addressing critical unmet medical needs in pediatric brain cancer.
Gate2Brain, a biotechnology company developing peptide-based delivery technology for central nervous system diseases, announced a strategic partnership with Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited.
A Strategic Milestone for Gate2Brain
Shilpa Biocare has become a strategic shareholder in Gate2Brain through a €7 million investment corresponding to a 30.4% equity stake. The partnership represents a major milestone for Gate2Brain and the largest investment raised by the company to date, underscoring the company’s growth and progress in less than six years since its foundation.
Advancing G2B-002 and CNS Drug Delivery
A key focus of the partnership is G2B-002, Gate2Brain’s lead candidate and a first-in-class therapeutic candidate for aggressive pediatric and adult brain tumors. G2B-002 has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
G2B-002 uses Gate2Brain’s proprietary MiniAp4 peptide shuttle to address one of the major challenges in central nervous system diseases: enabling therapeutics to cross the blood-brain barrier. Preclinical studies have demonstrated improved brain delivery and reduced side effects in pediatric brain tumors.
By combining Gate2Brain’s technology with Shilpa’s expertise in manufacturing, CMC development and regulatory strategy, the partnership aims to accelerate the development of G2B-002 while supporting the expansion of the company’s technology platform into additional therapeutic areas and CNS applications.
This collaboration marks an important step in advancing G2B-002 from preclinical development toward clinical application, while reinforcing Gate2Brain’s mission to address critical unmet medical needs in pediatric brain cancer and other central nervous system diseases, increasing the potential to deliver therapies to children and families facing devastating brain tumors.
“Gate2Brain acknowledges the continued support of its institutional partners, external advisors, investors and business angels, whose confidence and commitment have played a key role in advancing the company’s mission and technology platform”, said Dr. Meritxell Teixidó, Gate2Brain CEO & CSO.
About Gate2Brain
Gate2Brain is a biotechnology company founded in 2020 as a spin-off from IRB Barcelona, the University of Barcelona and Hospital Sant Joan de Déu Barcelona.
The company is advancing its proprietary technology platform to address high unmet medical needs in pediatric and adult brain tumors, as well as other central nervous system diseases.
Gate2Brain has received support from leading public and private institutions, including Fundación Botín (Mind the Gap), Banco Sabadell (BStartup Health), CDTI Innovación, the European Innovation Council (EIC Accelerator), ACCIÓ Startup Capital, and Fundación ”la Caixa”.
About Shilpa Medicare
Shilpa Medicare Limited is a global pharmaceutical company focused on oncology, biologics, complex formulations and CDMO services.
The company has expertise in manufacturing, regulatory development and commercialization, serving patients in more than 80 countries worldwide.
